Bottom line
MOTS-c is a peptide, a chain of 16 amino acids. The body makes it from the DNA inside mitochondria. Research has linked it to metabolism (how the body uses energy) and to exercise. Studies in people have measured the MOTS-c the body makes on its own. But the FDA (the U.S. agency that regulates medicines) found no studies of MOTS-c given to people as a treatment. It also found no data from people given MOTS-c in any way. Its benefits and risks as a treatment are unknown.389
- Evidence in people
- No useful studies of MOTS-c given to people were found
- Approval status
- MOTS-c is not approved by the FDA. The FDA reviewed two forms, MOTS-c free base and MOTS-c acetate. Neither one is an ingredient in an FDA-approved drug. In July 2026, FDA staff concluded that the evidence weighed against adding either form to the 503A Bulks List (the FDA's list of ingredients pharmacies may use to make custom medicines).312
- Biggest unknown
- The open question is about a well-defined MOTS-c product, meaning one whose makeup is clearly known. Given to people, would it bring a benefit they would notice that outweighs the risks? Measuring the body's own MOTS-c cannot answer this. Neither can treating cells and mice with it. In people, these all remain unknown: how much reaches the body, its effects on health, its safety, and its effects on longevity.39
Where research exists
Filled markers show which stages of research this guide covers. They don't rate how well MOTS-c works, how safe it is, or how good the studies are.
- Health results in peopleNo useful evidence found
- Blood tests and body measurements in peopleCovered in this guide
- Animal studiesCovered in this guide
- Lab studies in cellsCovered in this guide
- Untested idea or marketing claimCovered in this guide
What MOTS-c is
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a peptide made of 16 amino acids. It is coded by a short stretch of genetic code (an open reading frame) linked to mitochondrial 12S rRNA.38
The body makes its own MOTS-c, and researchers can measure it. A lab-made MOTS-c product given as a treatment raises separate questions. These include what exactly is in it, how it is given, and how much reaches the body. They also include how the body breaks it down, how the immune system responds, and what it does for patients.83
MOTS-c free base and MOTS-c acetate are different active drug ingredients. Compounding means a pharmacy making a custom medicine. A nomination asks the FDA to consider an ingredient for a compounding list. The FDA found the MOTS-c nomination unclear about which form was meant. It reviewed both forms separately.32
MOTS-c is a common name. It has no United States Adopted Name (an official U.S. name for a drug ingredient). The FDA reported that names and ID codes were used inconsistently, both in the nomination and in products on the market. That can make it hard to tell which form a certificate, product, or claim is about.3
Why scientists are interested in MOTS-c
The early work that started this research linked MOTS-c with metabolism inside cells. It also linked MOTS-c with signaling in skeletal muscle (the muscles that move the body). Other links were to insulin sensitivity, which is how well the body responds to insulin, and to biology tied to AMPK. AMPK is an enzyme that senses energy levels in cells. Those findings opened a reasonable line of research. That is a long way from an approved treatment claim.8
A later study found that exercise was linked to changes in the body's own MOTS-c, in human muscle and blood. The results on physical performance and aging came from giving MOTS-c to cells and mice. The human and animal results appear in the same paper. That makes it easy to read too much into them.9
MOTS-c has been promoted for many uses. These include insulin resistance (when the body responds poorly to insulin), obesity, osteoporosis (weak bones), and vascular calcification (calcium build-up in blood vessels). They also include muscle/fat metabolism, longevity, weight loss, energy regulation, and physical performance. The FDA found no evidence from giving MOTS-c to people that shows it works for those uses.3
Longevity is an especially hard claim to back up. A change in a body pathway cannot show that a product given to people extends human life or healthspan (years lived in good health). Neither can a marker that shifts with exercise, or an old mouse's treadmill result.93
Studies in people
In the human part of a 2021 study, ten young men exercised on a stationary bicycle. Researchers measured the body's own MOTS-c in their muscle and blood. No one in the study was given MOTS-c.9
This part of the study only observed, and no treatment was given. It supports the idea that the body's own MOTS-c responds to exercise. It cannot show that lab-made MOTS-c, injected or given another way, improves performance, metabolism, aging, or disease outcomes.93
The FDA found no studies of MOTS-c in people and no data from people given it in any way. It found no study in people of how the body absorbs, spreads and clears MOTS-c. It also found no study of MOTS-c given to people that supports the uses named in the nomination.3
Finding MOTS-c in human plasma (the liquid part of blood) leaves several questions open. So does seeing it change with exercise. These include how much MOTS-c could safely be given, and the therapeutic window (the range of doses that help without causing unacceptable harm). They also include any effect on patients' health, and whether the benefits outweigh the risks.893
Cell and mouse studies
The 2015 paper reported effects on metabolism in cells grown in a lab and in mice. These included results in mice with obesity and insulin resistance brought on by diet. These are animal and lab findings, from treating cells and mice.8
The 2021 paper reported results on physical performance and aging after treating young, middle-aged, and old mice with MOTS-c. Its human part measured the body's own response to exercise. The paper gave no MOTS-c to people.9
The FDA noted that it is still unclear which molecules MOTS-c acts on to cause its reported effects. It is also hard to predict which organs it may affect. This gap in knowing how it works matters when weighing both its benefits and its unintended effects.3
Testing MOTS-c as a treatment for people would need several things. It would need a clearly defined material. It would need data on how much reaches the body and how the body breaks it down. It would need lab and animal tests for harmful effects. And it would need controlled studies in patients, measuring outcomes specific to each condition it would be tested for. Controlled studies compare people who get a treatment with people who don't. The existing cell and mouse findings leave those steps unfinished.37
Safety and product quality
In a test-tube experiment, MOTS-c broke down quickly in human blood. The FDA said it is still unknown whether MOTS-c given to people could reach levels that have a drug effect over time. Blood in a lab tube cannot stand in for a study of how people's bodies absorb, spread and clear it.3
The FDA found no lab or animal studies of harmful effects, short-term or otherwise, good enough to guide possible use in patients. It also found no safety data from studies in people. So the possible safety risks for people are unknown.3
The FDA searched its safety-monitoring records and found no reports of side effects. But many section 503A compounders do not routinely report side effects to the FDA. These are pharmacies that make custom medicines under section 503A of the law. Because of that, an empty search says little about whether side effects happen.3
The FDA raised a possible concern for an injected peptide: the body's immune system might react against it. Clumping of the peptide molecules (aggregation) and peptide-related impurities may make this worse. The FDA found no studies in people that checked for immune reactions or clumping with MOTS-c-related substances.36
For a proposed injectable product, many qualities are critical to safety. These include its identity, sterility (being free of living germs), bacterial endotoxin (toxins from bacteria), and tiny particles. They also include its strength, impurities, clumping, how well it dissolves, and microbiological quality (wider checks for germs). The FDA found important gaps in the checks on those qualities for both forms it reviewed.34
What the FDA review means
The MOTS-c nomination was withdrawn. It was also unclear about whether it covered free base or acetate. The FDA chose to review both substances on its own.3
The nomination named insulin resistance, obesity, osteoporosis, vascular calcification, muscle/fat metabolism, and longevity. The FDA said the nomination did not have enough information for those uses. It also found no relevant studies that gave MOTS-c to people.3
The July 2026 review looked at whether MOTS-c might be placed on the 503A Bulks List. It was a compounding review. No finished MOTS-c drug was up for FDA approval.32
FDA staff concluded that several factors weighed against adding both forms to the 503A Bulks List. Too little was known about exactly what each form is. Their past use in compounding was unknown. Safety and effectiveness data from people were missing. And the safety information from lab and animal studies was not good enough.3
The advisory committee in this review is the Pharmacy Compounding Advisory Committee (a panel that advises the FDA on compounding). Its advice is nonbinding, meaning the FDA does not have to follow it. Its meeting approves nothing. A recommendation against putting MOTS-c on the list also stops short of banning the peptide in every legal or research setting.51
MOTS-c is listed on a current FDA page about compounding ingredients that may pose safety risks. The page points out the missing information on people given MOTS-c. It also flags concerns about immune reactions, clumping, and impurities. The page is a regulatory summary focused on risk. It makes no claim to have measured every possible harm.4
Questions to ask about a MOTS-c claim
Did a study measure the body's own MOTS-c? Did it give lab-made MOTS-c to cells or animals? Or did it give a clearly defined product to people? Those study designs answer different questions.893
Is the claim about a body pathway, a biomarker (a measurable sign in the body), mouse performance, human symptoms, disease outcomes, or lifespan? Does the cited evidence measure that same outcome, in the group the claim is about?93
Which form and which finished product are being discussed? What evidence covers what it is, its purity, its sterility, and bacterial endotoxin? And what evidence covers clumping, immune risk, how much reaches people's bodies, and how side effects would be detected?36
How the compounding review works
The July 2026 meeting dealt with a compounding process set by law. This process is separate from FDA drug approval. It has four steps.
- A substance is nominated
A nomination asks the FDA to consider whether a bulk drug substance (an active ingredient in raw form) may qualify for a compounding list set by law. Drug approval needs a separate application. - FDA staff assess the record
The FDA looks at what is known about exactly what the substance is. It also looks at past use, how well it works, and how safe it is, in light of the nomination. It prepares a public briefing memo as well. - The advisory committee gives nonbinding advice
The Pharmacy Compounding Advisory Committee discusses the questions and advises the FDA. Its recommendation is advice only. It approves nothing. - FDA considers final agency action
The FDA weighs the committee's input and completes its reviews. Only after that would it take any final agency action (an official FDA decision). A meeting or a staff position on its own never counts as that final step.
A staff memo is the staff's assessment, and an advisory committee recommendation is advice. Neither is an FDA decision.
References
- 1July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration · 2026-07-23 · FDA document
The meeting record lists the substances proposed for the list and the uses discussed. The committee's votes are advice only. They are not an FDA approval or a final FDA decision.
- 22026 PCAC Voting QuestionsU.S. Food and Drug Administration · 2026-07-23 · FDA document
The questions ask whether the free-base and acetate forms should be placed on the 503A bulks list. Drug approval was outside their scope.
- 3MOTS-c Free Base and Acetate Salt: Pharmacy Compounding Advisory Committee Briefing DocumentU.S. Food and Drug Administration · 2026-07-23 · FDA document
FDA identified no studies that gave MOTS-c to humans. Measuring the body's own MOTS-c in people is a different thing from testing it as a treatment.
- 4Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration · 2026-07-23 · FDA document
FDA's current compounding-risk summary includes BPC-157, KPV, MOTS-c, and the thymosin beta-4 fragment known as TB-500. The listing flags risks and stops well short of a complete safety profile.
- 5Advisory Committees: Critical to the FDA's Product Review ProcessU.S. Food and Drug Administration · 2018-01-04 · FDA document
The FDA explains that the committee only gives advice, which the FDA does not have to follow, and that the FDA makes the final decision.
- 6Immunogenicity Risk of Peptide Drug Products: Scientific and Regulatory ConsiderationsU.S. Food and Drug Administration · 2024-09-11 · FDA document
How a peptide is made up and given, clumping, and impurities can all change the risk of immune reactions. This is a general rule. Each product still has to be tested on its own.
- 7Clinical Pharmacology Considerations for Peptide Drug ProductsU.S. Food and Drug Administration · 2023-12-01 · FDA document
This is draft advice from the FDA, which drug makers do not have to follow, on developing peptide drugs. It lists questions each product must answer: how the body absorbs and clears it, use in people with liver or kidney problems, drug interactions, effects on heart rhythm, and immune reactions.
- 8The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin ResistanceCell Metabolism (PubMed record) · 2015-03-03 · Animal or lab study
The intervention results came from cells and mice. Detecting endogenous MOTS-c in human plasma measures the body's own peptide and tests no treatment.
- 9MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle HomeostasisNature Communications (PubMed record) · 2021-01-20 · Study in people
The part in people measured the body's own MOTS-c around exercise in ten young men. The results on giving MOTS-c, for fitness and aging, came from cells and mice.